NIKA PHARMACEUTICALS, INC.: 10-Q filed 2022-08-22
What NIKA PHARMACEUTICALS, INC. reported in its quarterly report filed 2022-08-22 (fiscal Q2 2022): 24 published measures, 71 facts as tagged in accession 0001826466-22-000111.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-08-22
- Fiscal period
- fiscal Q2 2022
- Accession
- 0001826466-22-000111 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NIKA PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 8,545 | USD | |
| At 2021-12-31 | 399 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 4,472 | USD | |
| At 2021-12-31 | 24,018 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 4,073 | USD | |
| At 2022-03-31 | 83 | USD | |
| At 2021-12-31 | -23,619 | USD | |
| At 2021-06-30 | -17,620 | USD | |
| At 2021-03-31 | -14,661 | USD | |
| At 2020-12-31 | -8,907 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 8,545 | USD | |
| At 2021-12-31 | 399 | USD | |
| At 2021-06-30 | 398 | USD | |
| At 2020-12-31 | 1,611 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 256,010 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 262,326 | USD | 181 |
| 2022-01-01 to 2022-03-31 | 6,316 | USD | 90 |
| 2021-04-01 to 2021-06-30 | 2,959 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 8,713 | USD | 181 |
| 2021-01-01 to 2021-03-31 | 5,754 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | -10,826 | USD | 181 |
| 2021-01-01 to 2021-06-30 | -8,713 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 18,972 | USD | 181 |
| 2021-01-01 to 2021-06-30 | 7,500 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 414,025 | USD | |
| At 2021-12-31 | 151,699 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 740,595,480 | shares | 91 |
| 2022-01-01 to 2022-06-30 | 569,294,430 | shares | 181 |
| 2021-04-01 to 2021-06-30 | 396,090,000 | shares | 91 |
| 2021-01-01 to 2021-06-30 | 396,090,000 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 740,595,480 | shares | 91 |
| 2022-01-01 to 2022-06-30 | 569,294,430 | shares | 181 |
| 2021-04-01 to 2021-06-30 | 396,090,000 | shares | 91 |
| 2021-01-01 to 2021-06-30 | 396,090,000 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 0 | USD/shares | 91 |
| 2022-01-01 to 2022-06-30 | 0 | USD/shares | 181 |
| 2021-04-01 to 2021-06-30 | 0 | USD/shares | 91 |
| 2021-01-01 to 2021-06-30 | 0 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 0 | USD/shares | 91 |
| 2022-01-01 to 2022-06-30 | 0 | USD/shares | 181 |
| 2021-04-01 to 2021-06-30 | 0 | USD/shares | 91 |
| 2021-01-01 to 2021-06-30 | 0 | USD/shares | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -256,010 | USD | 91 |
| 2022-01-01 to 2022-06-30 | -262,326 | USD | 181 |
| 2021-04-01 to 2021-06-30 | -2,959 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -8,713 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 8,545 | USD | |
| At 2021-12-31 | 399 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 4,472 | USD | |
| At 2021-12-31 | 10,518 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,500 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 10,000 | USD | 181 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 256,010 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 262,326 | USD | 181 |
| 2021-04-01 to 2021-06-30 | 2,959 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 8,713 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 876,090,000 | shares | |
| At 2021-12-31 | 396,090,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 320,489 | USD | |
| At 2021-12-31 | 88,471 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -256,010 | USD | 91 |
| 2022-01-01 to 2022-06-30 | -262,326 | USD | 181 |
| 2021-04-01 to 2021-06-30 | -2,959 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -8,713 | USD | 181 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | -262,326 | USD | 181 |
| 2021-01-01 to 2021-06-30 | -8,713 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 6,010 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 12,326 | USD | 181 |
| 2021-04-01 to 2021-06-30 | 2,959 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 8,713 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 1,500 | USD | 181 |
Inspect the source
- Entity
- NIKA PHARMACEUTICALS, INC. / CIK 0001145604
- Captured
- 2026-09-20T07:42:29.079Z
- SEC response SHA-256
72455d4e19d0f82286a99d0fa349659ab1ab793431c0cac82c5fb18286c89242
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001145604.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))